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Background: Fabry disease is a rare X-linked hereditary disorder (Xq22) caused by a deficiency in alpha-
galactosidase (α-GAL) activity. This enzyme deficit results in the systemic accumulation of glycophospholipids,
leading to multi-organ failure including the heart, kidneys, and brain. Enzyme replacement therapy (ERT) improves
the prognosis of patients with Fabry disease. We describe a case showing progressive renal failure despite ERT.
Case presentation: An 18-year-old obese male patient (body mass index (BMI) 29.9 kg/m2) was admitted for
detailed examination of mild degree hypertension (150/65 mmHg) and proteinuria occurring for 2 years prior to
admittance. Laboratory tests revealed mostly normal kidney function (serum creatinine 0.5 mg/dL, estimated
glomerular filtration rate 181 mL/min/m2) with low α-GAL activity, a significant level of proteinuria (0.5–1.0 g/day),
and the presence of mulberry cells in the urinary sediment. Renal biopsy demonstrated marked glomerulomegaly
with diffuse vacuolization of the glomerular epithelial cells and focal segmental glomerulosclerosis. Electron
microscopy revealed typical zebra bodies in the glomerular epithelial cells and effacement of foot processes of the
epithelium. We could not find any cause of glomerulomegaly except for obesity. α-GAL gene analysis revealed
a missense mutation in R301Q. Although ERT with agalsidase α was initiated, his renal function declined, and
hemodialysis was initiated at 22 years of age.
Conclusions: We present a case of rapid progression of Fabry nephropathy despite ERT. As with other renal
diseases, obesity may aggravate the progression of Fabry nephropathy.
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Fabry disease (FD) is a rare X-linked hereditary disorder
(Xq22) caused by a deficiency in alpha-galactosidase (α-
GAL) activity. Because of this mode of inheritance, men
usually become symptomatic while women are sometimes
asymptomatic carriers. α-GAL deficits result in the sys-
temic accumulation of glycophospholipids (globotriaosyl-
ceramide; Gb3), leading to multi-organ failure including
the heart, kidneys, and brain. The phenotype of FD is
variable. The classical phenotype includes severe neuro-
pathic or limb pain (acroparesthesias), which may be
precipitated by stress; extreme heat or cold and phys-
ical exertion; heat intolerance (usually associated with
exercise intolerance and avoidance of outdoors in sum-
mer months); decreased tear, saliva, or sweat produc-
tion (hypohidrosis); and cutaneous vascular lesions
(angiokeratomas). Renal manifestations occur in at least
50% of male patients and approximately 20% of female
patients [1, 2].
Newborn screening in Japan has demonstrated the in-
cidence of FD to be 0.14% [3]. In Japan, the prevalence
rate of FD in patients with left ventricular hypertrophy is
reported to be 3.0% and the prevalence in patients re-
ceiving dialysis is 0.02–1.2% [4–10]. Enzyme replacement
therapy (ERT) improves the prognosis of patients with FD
[11]; however, not all FD patients necessarily respond to
ERT. Factors for the low response to ERT include a low-
estimated glomerular filtration rate (eGFR) [12, 13], pro-
teinuria [14], and antibodies to agalsidase α [15].
Here, we describe a case of progressive renal failure
despite ERT. Renal biopsy showed glomerulomegaly and
focal segmental glomerulosclerosis (FSGS). Obesity may
have played an important role in the progression of
Fabry nephropathy (FN) in this patient. In addition, data
from three other patients with FD at our hospital further
support the conjecture that obesity worsens FN as with
other renal diseases.
Case presentation
An 18-year-old Japanese patient presented with protein-
uria 2 years prior to renal biopsy. He was admitted for
examination due to persistent proteinuria. On admis-
sion, his blood pressure was 150/65 mmHg, heart rate
was 80 beats per minute, height was 180 cm, and weight
was 97 kg with a body mass index of 29.9 kg/m2. Phys-
ical examination revealed no abnormalities except for
obesity and hypertension.
The serum creatinine level was 0.5 mg/dL, with an
eGFR of 181 mL/min/1.73 m2, 24-h creatinine clearance
rate of 124 mL/min, and proteinuria of 0.5–1.0 g/day.
The results of a complete blood count, as well as those
of serum glucose, lipid, electrolyte, and liver function
tests were all within the normal range. The hemoglobin
A1c content was 5.7%. Serum complement factor andimmunoglobulin levels were within the normal range. Mul-
berry cells were detected in the urinary sediment; therefore,
investigations for FD were conducted. Leukocyte alpha-
galactosidase (α-GAL) activity was 0.8 nmol/mg protein/h,
which was markedly low (normal range, 49.8–116.4 nmol/
mg protein/h).
The patient’s family tree is shown in Fig. 1. There was
no history of consanguineous marriage. The patient’s
father had a history of hypertension and aortic dissection
and had no characteristic symptoms of FD. His mother
had diabetes mellitus and dyslipidemia and was later
diagnosed with FD. The patient had two maternal un-
cles, both in good health. His paternal grandfather died
of acute myocardial infarction (AMI) at the age of 75 years.
His maternal grandfather had a history of AMI, under-
went pacemaker implantation, and died of pneumonia at
the age of 63 years. His maternal grandfather had six
siblings; the grandfather’s younger brother underwent
hemodialysis and died of undetermined causes at 49 years
of age. His maternal grandmother died of unknown causes
at the age of 77 years and displayed no indication of FD.
One elder sister was diagnosed with FD. Another elder
sister had not been investigated at this time. A summary
of all related cases of FD is presented in Table 1.
The patient did not present with any characteristic
symptoms of FD, such as pain in the extremities, angio-
keratomas, decreased sweating, or gastrointestinal disturb-
ance. Chest radiography showed no signs of cardiomegaly
or congestion, and the results of a 12-lead electrocardio-
gram were normal.
Renal biopsy was performed. Thirty-five glomeruli were
evaluated under light microscopy, all of which demon-
strated foamy changes in the podocytes (Fig. 2) and six
glomeruli had segmental sclerosis (Fig. 3). We classified
this FSGS as a perihilar variant according to the Columbia
classification [16]. The podocyte score was 3 according to
previous literature [17]. The glomeruli showed hyper-
trophy. Of the 35 glomeruli evaluated, 19 glomeruli had
intact Bowman’s capsules. The major length of those glom-
eruli was 270 ± 44 μm. An immunofluorescence study re-
vealed an intense deposition of C1q and C3c in the area of
the segmental sclerosis, with faint granular deposits of im-
munoglobulins G, A, and M at the same location. Electron
microscopy revealed no immune complex deposition
(Fig. 4). We concluded that there were no specific findings.
The patient had not taken medications in the past
(except temporarily for a cold) and had no history of any
infections, diabetes mellitus, or sickle cell anemia. There
was no evidence of prior nephron loss such as congeni-
tal absence, low birth weight, or surgical removal of a
kidney. He did not experience fever accompanied with
costovertebral angle tenderness. In addition, he had not
undergone cystourethrography. Thus, the possibility of
repeated pyelonephritis was low.
Fig. 1 Patient’s family tree. Squares denote men, circles denote women, and diamonds denote unknown gender. Oblique lines denote dead
individuals; question marks denote no information about the disease
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myelin-like inclusions in the cytoplasm of podocytes.
Effacement of the foot process was also observed (Fig. 4).
As these findings supported the diagnosis of FD, a final
diagnosis of the coexistence of obesity-related glomeru-
lopathy (ORG) and FD was established.
We prescribed lifestyle changes, such as the discon-
tinuation of smoking, increased exercise, and weight
reduction. ERT was initiated in order to slow progres-
sion of FD. Intravenous administration of agalsidase α at
a dose of 17.5 mg bi-weekly (0.2 mg/kg) was initiated.
At the time of ERT initiation, the patient’s serum cre-
atinine level was 0.62 mg/dL, urinary protein content
was 1.8 g/day, serum Gb3 level was 3.9 nmol/mL, and
urinary sediment Gb3 level was 1650 nmol/day. Other
laboratory findings were all within the normal range.
The patient continued ERT and his height and weight
increased. His height increased to 184 cm, and weight
increased to 113 kg (body mass index (BMI) = 33.4 kg/m2)
at the age of 20 years. We increased the dose of agalsidase
α to 21 mg (0.2 mg/kg) once the patient reached his
maximum height; after that, the dose was adjusted ac-
cording to his weight.At 20 years of age, the patient’s serum creatinine level
was elevated at 1.2 mg/dL (eGFR, 69 mL/min/1.73 m2),
proteinuria was 3.7 g/day, and total protein content was
6.7 g/dL. His systolic blood pressure was maintained at
130–140 mmHg with 16 mg of oral azelnidipine; renin-
angiotensin-aldosterone axis blockers and nephrotoxic
drugs such as nonsteroidal anti-inflammatory drugs were
not administered.
At the age of 21 years, his serum creatinine level had in-
creased to 2.95 mg/dL (eGFR, 25 mL/min/1.73 m2), pro-
teinuria was 3.4 g/day, and total protein content was
6.2 g/day. Systolic blood pressure was controlled at 130–
140 mmHg by using 16 mg of oral azelnidipine. Renal
function continued to decline, although no nephrotoxic
drugs were used. Ultrasound of the kidneys revealed bilat-
eral atrophy with a thin cortex. The patient’s serum
creatinine level ultimately reached 12.75 mg/dL, at which
point hemodialysis via an arterial–venous fistula was
initiated. ERT was continued along with maintenance
hemodialysis. Currently, 2 years since the initiation of
hemodialysis, the patient has not had any complications.
Following the initiation of hemodialysis, the patient
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Fig. 2 Periodic acid–Schiff staining findings on light microscopy.
Foamy changes in podocytes are visible (closed arrow)
Fig. 4 Electron microscopy findings. Open arrow: zebra bodies
(myelin-like inclusion) are visible in the podocytes. Closed arrow:
effacement of foot processes was also observed
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gene p.Arg301Gln. This missense mutation was described
according to standard mutation nomenclature in molecu-
lar diagnostics [18] and has been previously reported in
FD cases [19]. In this case, the patient’s mother also had
the same genetic mutation; however, she remained asymp-
tomatic and only had mild diabetes mellitus. Her α-GAL
activity was 13 nmol/mg protein/h, which is lower than
the normal level (20–80 nmol/mg protein/h). She did not
show any of the characteristic symptoms of FD, such as
pain in the extremities, angiokeratomas, decreased sweat-
ing, or gastrointestinal disturbance. Her serum creatinine
level was 0.51 mg/dl. She showed normal proteinuria
(0.1 g/gCre), but the urinary albumin level was 119 mg/
day. Her left ventricular mass index was 114.2 g/m2. She
had chronic kidney disease and mild cardiac hypertrophy.
She also underwent renal biopsy. Seventeen glomeruli wereFig. 3 Periodic acid–Schiff staining findings on light microscopy.
Segmental sclerosis of glomerulus is seen at the 4 to 6
o’clock positionevaluated under light microscopy, all of which demon-
strated foamy changes in the podocytes, and no glomeruli
had segmental sclerosis (Fig. 5). The podocyte score was 2.
The major length of the glomeruli was 231 ± 25 μm. Elec-
tron microscopy revealed zebra bodies. Her serum and
urine Gb3 level was under the detection level, but to avoid
further complication of FD, ERT with agalsidase α (0.2 mg/
kg bi-weekly) was initiated. Her condition was stable, with-
out any complications following ERT.
His elder sister also had the same mutation. She was
obese (160 cm, 111 kg, BMI 43.3 kg/m2) and had dia-
betes mellitus. She also did not show any of the charac-
teristic symptoms of FD, such as pain in the extremities,
angiokeratomas, decreased sweating, or gastrointestinal
disturbance. We recommended ERT because her α-GALFig. 5 Periodic acid–Schiff staining findings on light microscopy.
Foamy changes in podocytes are visible (closed arrow)
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and serum/urine Gb3 level was elevated (Table 1). How-
ever, as she decided not to initiate ERT, we only pre-
scribed lifestyle changes such as the discontinuation of
smoking, increased exercise, and weight reduction.
Discussion with mini-review of low responsiveness to ERT
This case showed aggressive progression of FN despite
ERT that was initiated when the patient still had normal
renal function. We review the literature and discuss
which factors could have contributed to the low respon-
siveness to ERT in this case.
Proteinuria and histological findings
A past report showed that more than 60% of a patient’s
kidney function was due to the response to ERT [20]. In
addition, the presence of proteinuria and advanced
histological finding is a predictor of progression. Pro-
teinuria is one of the known risk factors for renal failure.
Schiffmann et al. reported that untreated male patients
with FN and a baseline eGFR >60 mL/min/1.73 m2 were
found to progress at a mean rate of −2.93 mL/min/
1.73 m2/year, and the severity of proteinuria was found
to be associated with a more rapid loss of eGFR [14]. In
addition, this previous report showed that patients with
FN and proteinuria >1.0 g/g creatinine had a steeper
eGFR slope (−6.9 mL/min/1.73 m2/year). Similarly,
Warnnock et al. reported that proteinuria is associated
with the loss of renal function in FD [20]. Our patient
was at a high risk of renal failure owing to progressive
proteinuria.
ERT is one of the established therapies for FN. Both
types of ERT treatment (agalsidase α and agalsidase β)
can have a favorable effect on the kidneys [20–22].
Germain et al. reported that some FN patients treated
with agalsidase β demonstrated a steep eGFR slope. All
of those patients were in the high renal involvement
group (patients with urinary protein creatinine ratio
>0.5 g/g creatinine or ≥50% sclerotic glomeruli at base-
line), as was the patient in this study [13]. This suggests
that some FD patients have a weak response to ERT.
Fogo et al. showed that the podocyte vacuoles score
correlated with globotriosylceramides (GL-3) accumula-
tion [17]. In this case, the patient’s podocyte vacuoles
score was 3. Renal function should have decreased due
to advanced FN, but the presence of obesity most likely
caused hyperfiltration. These factors offset each other,
and he appeared to have normal renal function at the
time of presentation.
Presence of antibody to agalsidase α
Deegan suggested that the presence of a high-titer anti-
body to galactosidase might be a factor in the poor re-
sponse to ERT [15]. The incidence of antibodies observedduring agalsidase α is considered to be 0–56% [14]. How-
ever, the patient in this case did not have a high antibody
titer. A twofold or greater change in agalsidase-alpha-
specific quantitative antibody titers in paired sera was con-
sidered as significant.
Selection of antihypertensive drugs
The calcium channel blocker, azelnidipine, was used to
control the patient’s blood pressure. The systolic blood
pressure was maintained at 130–140 mmHg. It may have
been preferable to lower the systolic pressure further to less
than 130 mmHg, according to the current recommenda-
tion for the management of FN [12]. We could have added
other antihypertensive medications such as angiotensin-
converting enzyme inhibitors and angiotensin receptor
blockers that have renoprotective effects in FN. However,
the use of angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers is only 40–79% [12, 13].
Dose of ERT
The drug doses used in the ERT regimen may have been
too low. Tøndel et al. showed that the clearance of Gb3
from podocytes is dose dependent; however, this had little
impact on the decline in kidney function [22]. Schiffmann
et al. showed that weekly infusions of agalsidase α at a
dosage of 0.2 mg/kg might be beneficial [23]. In our study,
the patient demonstrated a continued decline in renal
function despite bi-weekly infusion of conventionally
dosed agalsidase α therapy (0.2 mg/kg every other week)
for 4 years. Weekly administration generally leads to a
slower decline in eGFR. If the Japanese insurance system
had allowed us to choose this option, we would have
increased the frequency of ERT.
Our patient showed a marked decline in eGFR 2 years
after ERT initiation while the patient was still in his
growth phase. He gained in height and weight during
the first 2 years of ERT therapy. Ries et al. reported that
a pediatric population (6–18 years old; mean age,
11.8 years) showed rapid clearance of agalsidase α [23],
which might have contributed to a weak response to
ERT in our patient.
Gene mutation and lyonization Future studies should
evaluate the correlation between the genetic mutation
type and disease prognosis. At present, at least 600 vari-
ants in the α-GAL gene have been described [24].
However, the relationship between the type of mutation
and prognosis is not clear. R301Q mutations cause sev-
eral phenotypes (http://fabry-database.org). For example,
cases of nephropathy only, classic type, and an atypical
variant have been reported [8, 25, 26]. In addition, Poli-
tei et al. revealed that patients with the same mutation
as the current case (L415P) show different organ damage
[27]. These findings suggest that gene mutation is not
Saito et al. Renal Replacement Therapy  (2016) 2:69 Page 7 of 9the only factor involved in organ damage. Acquired
factors may also be important.
Differences in gene mutations result in three different
functions of the alpha-GAL enzyme, including incomplete
protein (lack of enzyme activity), weak or no enzymatic
activity within the lysosome, or impairment in the transfer
of the protein from the endoplasmic reticulum (ER) to the
lysosome. R301Q alpha-GAL mutations result in the re-
tention of the abnormal protein in the ER, which are
degraded without processing [28]. Notably, our case also
had this gene mutation and poor renal prognosis.
Lyonization is also an important factor for females. The
mother and sister had the same mutation of the GLA gene
but showed a different phenotype, with a different level of
Gb3, potentially explainable by lyonization [29]. At the
moment, the degree of lyonization is unmeasurable.Present case
Despite the degree of proteinuria, our patient had an
extraordinarily steep eGFR curve (approximately −25 mL/
min/1.73 m2 per year). Renal biopsy revealed FSGS with
no other significant underlying factors except for obesity.
FN itself causes FSGS [30]. To our best knowledge, Fabry
disease itself did not cause the glomerulomegaly. The pa-
tient was obese and had nephrotic-range proteinuria in
the absence of nephrotic syndrome. The renal biopsy
specimen showed segmental sclerosis accompanied by
glomerulomegaly. These clinical presentations are similar
to those observed in previous reports on obesity-related
glomerulopathy ORG [31–33]. From a clinical point of
view, a high eGFR value at the time of renal biopsy could
be explained by excessive filtration, which is similar to the
features observed in ORG. Therefore, we believe that
ORG played an important role in the rapid eGFR decline
in our patient’s FN.
Obesity is known as a risk factor for end-stage renal
disease (ESRD) [34–38]. In addition, when patients have
a risk factor for ESRD, including unilateral kidney after
nephrectomy and IgA nephropathy, obesity is known to
affect the progression of chronic kidney disease (CKD)
[32, 39, 40]. A relationship between obesity and FN has
not previously been investigated. FD patients are gener-
ally lean, possibly due to gastrointestinal symptoms.
Only three published reports describe BMI and the fre-
quency of obesity in FD [40–42]. Of four patients
with FD at our hospital, the three obese patients showed
progressive FN (Table 1). Although the sample size is
too small to indicate obesity as the culprit, we believe
that obesity exacerbates FN as with other renal diseases.
FD is a rare disease, and it is currently not possible to
anticipate which patients will have a weak response to
ERT. Importantly, we can prescribe lifestyle changes to
reduce weight, which may improve the prognosis forobese patients with FD. Future studies should focus on a
potential correlation between obesity and FN.
In order to determine the factors, genotype, and severity
of histology that promote renal dysfunction in FN, as well
as the optimal dose of ERT for treatment of FN, all FD
cases should be reported globally. Moreover, as FD is a
rare disease, its early detection is also important. One
useful test in FN screening involves the detection of mul-
berry cells in urinary sediment, which has a low cost and
is less invasive than other tests such as renal biopsy or
gene analysis [43]. All of our four cases presented with
mulberry cells in their urine sediment. Mulberry cells are
very small (usually <10 μm) and require training to detect.
In addition, a method for the early detection of FD needs
to be established to avoid subsequent organ failure.
Conclusions
To the best of our knowledge, this is the first report sug-
gesting that obesity accelerates the progression of FN.
Renal histology showed remarkable glomerulomegaly. In
addition, this case is a unique example of a different
manifestation of FD with a poor response of FN to ERT.
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